Alembic announces USFDA final approval for single-dose vials
Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma
Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Review will evaluate effectiveness in treating alcohol withdrawal syndrome and supporting abstinence, as well as measures to mitigate risk of abuse
Star Health Insurance is modernising its claims ecosystem to be future-ready
The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability
Changhua site meets international regulatory standards for global medical applications
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
This collaboration ensures that patients receive comprehensive care, including emotional and psychological support throughout their fertility journey
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
Subscribe To Our Newsletter & Stay Updated